NRG Therapeutics has shared preclinical and mechanistic data of its lead clinical asset NRG5051, a treatment for amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND), and Parkinson’s. NRG disclosed that NRG5051, a first-in-class, orally bioavailable and CNS-penetrant next-generation inhibitor of the mitochondrial permeability transition… Read More
NRG Therapeutics has announced the appointment of Dr Claus Sundgreen as Chief Medical Officer (CMO), effective from 1 August 2026. A recognised leader in neuroscience drug development with expertise in ALS, Dr Sundgreen brings over 25 years of clinical leadership with experience spanning translational medicine and all… Read More
The first participants have been dosed in the first-in-human Phase I clinical trial of NRG Therapeutics’ lead candidate NRG5051, which is being developed as a treatment for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) and Parkinson’s. NRG5051 is a first-in-class, orally bioavailable and CNS-penetrant next-generation inhibitor of the mitochondrial… Read More
NRG Therapeutics has expanded its team with the appointment of Paul Thompson PhD as Chief Development Officer (CDO). In his role at NRG, Thompson will be project lead for NRG5051 which is on track to commence first-in-human studies in early 2026. NRG5051 is an oral,… Read More
Neuroscience company NRG Therapeutics has announced an expansion to its senior team as it advances its neurodegenerative disease treatment NRG5051. Sarah Almond has been appointed as VP of Translational Biology, David Brocklebank as Director of Clinical Operations, and Kathryn Oliver as Director of Project Management. … Read More
NRG Therapeutics has been awarded a $5 million grant from The Michael J Fox Foundation for Parkinson’s Research (MJFF) to support the development of NRG5051 as a novel disease-modifying treatment for Parkinson’s disease. The company says NRG5051 also has potential in other neurological diseases such as… Read More
NRG Therapeutics has been awarded a non-dilutive grant from Target ALS Foundation to support its discovery programme for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease or motor neurone disease. It is one of five recipients of the 2024 In Vivo Target Validation grants… Read More
